Exercise of options and total voting rights
Fusion Antibodies plc announced the exercise of options by an employee, resulting in the issuance of 135,000 new ordinary shares at an exercise price of 4.25p per share. These new shares are expected to be admitted to trading on AIM on or around June 8, 2026. Following this issuance, the Company's total number of ordinary shares in issue will be 125,156,878, with no shares held in treasury, which shareholders can use for notification calculations under the FCA's Disclosure Guidance and Transparency Rules.
Select text to share a quote on X · sign in to keep highlights & notes in your FAB notes
Fusion Antibodies plc (AIM: FAB), specialists in pre-clinical antibody discovery, engineering and supply for both therapeutic drug and diagnostic applications, announces the exercise of options by an employee of the Company.
The employee has exercised options over 135,000 ordinary shares of 4p each in the Company ("Ordinary Shares") at an exercise price of 4.25p per option. To satisfy the exercise the Company is issuing 135,000 new Ordinary Shares (the "New Ordinary Shares"). Application has been made to the London Stock Exchange for the New Ordinary Shares to be admitted to trading on AIM ("Admission") and it is expected that Admission will be effective, and dealings will commence in respect of the New Ordinary Shares at 8.00 a.m. on or around 8 June 2026.
Following Admission, the Company will have 125,156,878 Ordinary Shares in issue. The Company does not currently hold any shares in treasury and therefore this figure may be used by shareholders in the Company as the denominator for the calculation by which they may determine if they are required to notify their interest in, or change to their interest in, the share capital of the Company under the FCA's Disclosure Guidance and Transparency Rules.
Cleaned text: letterheads, contacts and legal notices removed. View the original announcement ↗ · Company filings. Not investment advice.